newsfilter

Outlook of Nov 11, 2026. Latest Health Information Services outlook →

Health Information Services — industry outlook

  • Period: 2026-10-21 to 2026-11-11
  • Events: 23
  • Generated: 2026-11-11T07:30:00.005Z

Profitability and Guidance Revisions

Multiple companies raised or reaffirmed full-year 2026 financial guidance, signaling confidence in near-term execution despite macro headwinds. Celera Corp (CRA) raised FY26 Revenue guidance to $12.065 billion–$12.105 billion and Adjusted EPS to $11.25–$11.35. BrightSpring Health Services (BTSG) projects 2026 Adjusted EBITDA of $850 million–$860 million and FY27 Adjusted EBITDA growth of 15%–20% organic. Hinge Health (HNGE) raised FY26 Revenue to $879 million–$881 million and operating margin midpoint to 30%, though it lowered its FY27 gross margin target to ~85% from 88% due to care team hiring. Claritev Corp (CTEV) raised FY26 Revenue to $1.038 billion–$1.043 billion and EBITDA to $625 million–$630 million, targeting >60% margins. GenEdx Holdings (WGS) raised Adjusted net income to ≥$12 million and Adjusted gross margin to ~71%. Progyny (PGNY) raised FY26 Adjusted EBITDA to $235 million–$240 million and EPS to $2.09–$2.13. Solventum (SOLV) raised FY26 EPS to $7.20–$7.30 and Operating Margin toward the high end of 22.2%–22.7%. Amwell (AMWL) raised FY26 Revenue to $204 million–$206 million and reduced the full-year Adjusted EBITDA loss to $6.9 million–$7.9 million.

Pricing Power and PAMA Headwinds

The industry is bifurcated regarding PAMA (Pricing and Payment Act) impacts. Independent labs and genetic testing firms face explicit mid-single-digit headwinds, while payers and technology platforms anticipate structural shifts. Celera Corp (CRA) estimates PAMA impacts at ~1% of 2026 revenues, with cumulative 2027–2029 impact at <1.3%, advocating for the "Results Act" to correct CMS data weighting (reported 76.5% vs. actual <10% share for independents). GenEdx Holdings (WGS) notes 45% of revenue is exposed to PAMA, expecting a mid-single-digit headwind in 2027, though it anticipates this will be fully offset by RCM improvements. However, Teladoc Health (TDOC) and Omada Health (OMDA) highlight broader price inflation pressures. Omada projects employer benefit costs rising 8.2% in 2027, while Amwell (AMWL) expects costs to rise 8%–11%. Conversely, GE HealthCare (GEHC) sees pricing as a lever to offset inflation, with expected pricing windows of 1%–2% for differentiated platforms. Tempus (TEM) expects minimal PAMA impact on hereditary cancer ASPs, anticipating ASP uplifts of ~$80 million in 2027 via FDA approvals.

AI Integration and Commercialization

Artificial Intelligence is transitioning from a cost-saving tool to a revenue generator and operational core across the sector. Hinge Health (HNGE) expects AI to drive 46% revenue growth in Q4 and plans to launch AI agents in production with a goal of 60–80% of code delivered via AI by year-end. Doximity (DOCS) is monetizing AI Search with 16 of the top 20 pharma clients, projecting an eight-figure product ramping throughout 2027. Waystar (WAY) attributes 43% of Q3 bookings to Altitude AI, with autonomous claim resubmission capabilities projected to save 400,000+ hours annually. Teladoc (TDOC) is launching "Teladoc One" in 2027, integrating AI-driven insights like contact-free vitals and ambient documentation. Evolent Health (EVH) claims market leadership in AI prior auth, targeting 80% of manual cases (approx. 2 million) processed by Auth Intelligence by end-2027. SOPHiA Genetics (SOPH) leverages 118,000+ monthly analyses to train its "Collective Intelligence" and is expanding into clinical decision support tools.

Strategic Growth Drivers: M&A and Vertical Expansion

Acquisitions and vertical integration are central to 2027 growth strategies. BrightSpring (BTSG) plans to pursue larger transactions (potentially $20M+ EBITDA) and views 2027 as a year of opportunity for organic growth and acquisitions. Solventum (SOLV) is separating Health Information Systems (HIS) by end-2027 and integrating Acera to drive NPWT growth. Tempus (TEM) is closing its Personalis acquisition in November 2026, anticipating a turn to positive gross profit per MRD test mid-to-late 2027. Celera (CRA) finalized an acquisition of Northeastern health system outreach assets to close later this year. Privia Health (PRVA) is acquiring American Choice Healthcare for $36M cash to expand into 10 new states by Jan 2027 and expects to maintain a $520 million cash balance. Hinge Health (HNGE) intends to use M&A only to accelerate timelines for hardware tuck-ins in MSK, GI, and migraine.

Product Innovation and Clinical Differentiation

Companies are launching new diagnostic and therapeutic products to capture specific market segments. Celera (CRA) is rolling out Roche P-Tau 217 for Alzheimer's and a partnership with Waters Corp for an OnClarity self-collection kit in 2027. GE HealthCare (GEHC) expects Forcado to reach a $500 million run rate by FY2028 and is investing in an MR manganese contrast agent targeting a $1.2 billion market. SOPHiA Genetics (SOPH) expects MSK Access liquid biopsy to be installed in 100 institutions globally, with a focus on CDX deals. Progyny (PGNY) sees 100% attach rates for Progeny Rx among new clients and projects 3 million lives will utilize expanded products beyond RX in 2027. Tempus (TEM) anticipates a 32% unit growth in Oncology Diagnostics in Q3 2026, driven by XT and XF test approvals.

Operational Efficiencies and Cost Structures

Efforts to offset inflation and operational drag are prominent. Celera (CRA) expects its "Invigorate" program to deliver 3% in annual cost savings, offsetting ~$120M in wage inflation and $14M in fuel costs. Solventum (SOLV) expects 100 bps of margin expansion excluding tariff refunds and aims for a 23%–25% operating margin by 2028. Hinge Health (HNGE) targets 85% gross margins in 2027, accepting lower short-term margins to fund care team hiring. Progyny (PGNY) plans to taper investment cycles in 2027 to allow incremental gross profit to flow to EBITDA. Amwell (AMWL) is shifting to outcome-based pricing models and expects Q4 2026 to reach positive Adjusted EBITDA. HealthStream (HSTM) faces short-term margin pressure from an AWS cloud migration expected to complete in 2027, offset by long-term efficiency gains.